Role of Serum Tumor Markers in Prognosis of Operable Non-small Cell Lung Cancer Patients

Abstract

Objective To evaluate the prognostic value of CEA, CA125, CA199, NSE, CYFRA21-1 and SCC-Ag as serum tumor markers on the diagnosis of operable non-small cell lung cancer(NSCLC) after radical operation. Methods We reviewed 1851 consecutive NSCLC patients who underwent radical resection from January 2005 to December 2014. We used analysis of variance (ANOVA) to analyze the associations between tumor markers and pathological stage. Survival probability was estimated by the Kaplan-Meier method. Cox proportional hazards regression was used to identify independent prognostic factors. Results The positive rates of CEA, CA125, CA199, CYFRA21-1 and SCC-Ag in stage Ⅱ and Ⅲ NSCLC were higher than those in stageⅠ(P < 0.001), but there was not significant difference among different stages for NSE (P=0.743). The overall survival in negative group of CEA, CA125, CA199 and CYFRA21-1 were better than those in positive group respectively (P < 0.05), but the survival in positive group of NSE was better than that in negative group (P=0.033). SCC-Ag negative group had longer survival time than SCC-Ag positive group, without statistically significant difference (P=0.072). CEA (HR=1.572, 95%CI: 1.117-2.214, P=0.010), CA125(HR=2.464, 95%CI: 1.610-3.772, P < 0.001), CYFRA21-1 (HR=1.445, 95%CI: 1.044-2.000, P=0.027) were detected to be independent risk factors for the prognosis of NSCLC patients. Conclusion CEA, CA125 and CYFRA21-1 play an important role prior to CA199, NSE and SCC-Ag in predicting severity and prognosis of NSCLC patients.

Keywords

• tumor marker
• nsclc
• cea
• ca125
• ca199
• cyfra21-1